# COVID-19 Methylene Blue Antiviral Treatment

> **NCT05004805** · PHASE2 · COMPLETED · sponsor: **Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences** · enrollment: 24 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Methylene Blue
- **DRUG:** Saline nasal spray

## Key facts

- **NCT ID:** NCT05004805
- **Lead sponsor:** Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-06
- **Primary completion:** 2021-12-12
- **Final completion:** 2021-12-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05004805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05004805, "COVID-19 Methylene Blue Antiviral Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05004805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*